Free Trial

Monashee Investment Management LLC Acquires New Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Aclaris Therapeutics logo with Medical background

Monashee Investment Management LLC bought a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 888,888 shares of the biotechnology company's stock, valued at approximately $2,204,000. Aclaris Therapeutics accounts for about 0.3% of Monashee Investment Management LLC's investment portfolio, making the stock its 25th largest holding. Monashee Investment Management LLC owned approximately 1.24% of Aclaris Therapeutics at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ACRS. ExodusPoint Capital Management LP acquired a new stake in Aclaris Therapeutics during the 4th quarter worth about $26,000. Invesco Ltd. acquired a new position in Aclaris Therapeutics in the 4th quarter worth approximately $28,000. Commonwealth Equity Services LLC acquired a new stake in Aclaris Therapeutics during the 4th quarter valued at $36,000. Alpine Global Management LLC purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at $38,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter worth $82,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Stock Down 7.3 %

ACRS stock traded down $0.11 during trading hours on Monday, hitting $1.34. The company's stock had a trading volume of 148,861 shares, compared to its average volume of 1,181,949. The stock has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $2.25. Aclaris Therapeutics, Inc. has a 12 month low of $0.95 and a 12 month high of $5.17. The company has a market capitalization of $144.56 million, a PE ratio of -2.57 and a beta of 0.42.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ACRS shares. Cantor Fitzgerald assumed coverage on Aclaris Therapeutics in a research note on Tuesday, March 18th. They issued an "overweight" rating for the company. StockNews.com cut shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 8th. Finally, Scotiabank began coverage on shares of Aclaris Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Read Our Latest Analysis on Aclaris Therapeutics

Aclaris Therapeutics Company Profile

(Free Report)

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

See Also

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Should You Invest $1,000 in Aclaris Therapeutics Right Now?

Before you consider Aclaris Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.

While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines